BLOOMBERG LAW WEBINAR: Interpreting Myriad: Gene Patenting and Other Inventions at Risk
Join Bloomberg Law for a complimentary webinar that will provide an assessment of the June 13 Supreme Court opinion in Association for Molecular Pathology v. Myriad Genetics Inc. The court considered a fundamental question: Are human genes patentable? But the patent community had a broader concern—the high court’s recent statements that seem to question patent eligibility on a number of other fronts. Did the justices limit their review or did they deal a significant blow to a broad swath of patents? A panel of legal experts will review the legal arguments and gauge the potential impact on biotechnology and other markets.
Key topics covered during this event include:
> Did the court tilt to becoming more or less patentee-friendly?
> What precedent was set?
> What will the impact be on patenting in the biotechnology industry?
> What will the impact be on the biotechnology industry?
> How will the court’s decision affect other technologies?
> What will this mean to parties currently involved in patent infringement litigation?
> How should patent applicants proceed? How should patent owners proceed?
Hon. Paul Redmond Michel
Former Chief Judge
The United States Court of Appeals for the Federal Circuit
Discussion moderated by Tony Dutra, Legal Editor, Bloomberg BNA’s Patent, Trademark & Copyright Journal®.